FindTrial
Sign In

STI571

DRUG5 trials

Sponsors

Novartis Pharmaceuticals, University of Bologna

Conditions

3rd Line GISTChronic Eosinophilic Leukemia (CEL)Chronic Myeloid LeukemiaHypereosinophilic SyndromeLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMyeloproliferative DisordersSystemic Sclerosis, Scleroderma

Phase 1

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
CompletedNCT01468688
Novartis Pharmaceuticals3rd Line GIST
Start: 2012-04-20End: 2016-07-29Updated: 2020-12-21

Phase 2

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
CompletedNCT00171223
Novartis PharmaceuticalsLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Start: 1999-12-06End: 2013-11-29Updated: 2021-07-22
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
NCT00276926
University of BolognaChronic Eosinophilic Leukemia (CEL), Hypereosinophilic Syndrome, Myeloproliferative Disorders
Start: 2003-03-31Updated: 2009-09-15
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia
CompletedNCT00511303
University of BolognaChronic Myeloid Leukemia
Start: 2000-08-31Target: 200Updated: 2007-08-03
Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
CompletedNCT00613171
Novartis PharmaceuticalsSystemic Sclerosis, Scleroderma
Start: 2008-01-02End: 2010-01-13Updated: 2021-07-07

Related Papers

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
2020-03-0922 citations